Inhaled iloprost
Inhaled iloprost is a pharmaceutical drug with 7 clinical trials. Historical success rate of 60.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
50.0%
3 of 6 finished
50.0%
3 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide
Inhaled Iloprost for Suspected COVID-19 Respiratory Failure
Iloprost for Bridging to Heart Transplantation in PH
The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery
Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation
Clinical Trials (7)
Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide
Inhaled Iloprost for Suspected COVID-19 Respiratory Failure
Iloprost for Bridging to Heart Transplantation in PH
The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery
Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation
Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.
Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7